BERLIN--(BUSINESS WIRE)--EBS Technologies (“EBS”) announced today it has opened its first ophthalmologic clinical site in Germany that is offering the use of the EBS NEXT WAVE™ brain stimulation device designed to expand the visual field of patients with impaired vision caused by glaucoma, stroke and other neurological diseases.
Last week, EBS announced that a clinical study (“Brain functional connectivity network breakdown and restoration in blindness”) published in the highly respected journal Neurology® validates non-invasive brain stimulation for restoring partial vision to an impaired eye; the Company’s NEXT WAVE™ system is a non-invasive brain stimulation device that is designed to expand the visual field of patients with impaired vision caused by glaucoma, stroke or other neurological disorders. NEXT WAVE™ is approved for sale in Europe.
Help employers find you! Check out all the jobs and post your resume.
